Literature DB >> 28923225

Randomized Clinical Trials in Colon and Rectal Cancer.

Atif Iqbal1, Thomas J George2.   

Abstract

Surgery remains the mainstay of treatment for colon and rectal cancers. Colon cancer outcomes have improved with laparoscopic techniques, enhanced recovery pathways, and adjuvant chemotherapy. Adjuvant 5-fluorouracil with or without oxaliplatin in stage III and possibly high-risk stage II colon cancer is associated with improved survival. Multimodality management of rectal cancer continues to evolve; total mesorectal excision is the cornerstone. Oncologic results do not support the use of laparoscopic resection in rectal cancer. Preoperative short- or long-course radiation for stage II or III rectal cancer is the standard of care. Long course chemoradiation is recommended for bulky tumors.
Copyright © 2017 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Adjuvant; Chemotherapy; Colon cancer; Colorectal cancer; Neoadjuvant; Radiation; Rectal cancer; Surgery

Mesh：

Substances：

Year:  2017        PMID： 28923225     DOI： 10.1016/j.soc.2017.05.008

Source DB:  PubMed          Journal:  Surg Oncol Clin N Am        ISSN： 1055-3207            Impact factor:   3.495


  17 in total

Review 1.  Comprehensive literature review of randomized clinical trials examining novel treatment advances in patients with colon cancer.

Authors:  William Paul Skelton; Aaron J Franke; Atif Iqbal; Thomas J George
Journal:  J Gastrointest Oncol       Date:  2020-08

2.  Association of IL-36γ with tertiary lymphoid structures and inflammatory immune infiltrates in human colorectal cancer.

Authors:  Aliyah M Weinstein; Nicolas A Giraldo; Florent Petitprez; Catherine Julie; Laetitia Lacroix; Frédérique Peschaud; Jean-François Emile; Laetitia Marisa; Wolf H Fridman; Walter J Storkus; Catherine Sautès-Fridman
Journal:  Cancer Immunol Immunother       Date:  2018-10-12       Impact factor: 6.968

3.  Gnetum montanum extract induces apoptosis by inhibiting the activation of AKT in SW480 human colon cancer cells.

Authors:  Xianglong Pan; Xiaotao Hou; Fan Zhang; Peiling Tang; Wanruo Wan; Zixia Su; Yeguo Yang; Wei Wei; Zhengcai Du; Jiagang Deng; Erwei Hao
Journal:  Pharm Biol       Date:  2022-12       Impact factor: 3.889

4.  Oxymatrine reverses 5-fluorouracil resistance by inhibition of colon cancer cell epithelial-mesenchymal transition and NF-κB signaling in vitro.

Authors:  Li Liang; Jun Wu; Jie Luo; Li Wang; Zu Xuan Chen; Cheng Long Han; Ting Qing Gan; Jie An Huang; Zheng Wen Cai
Journal:  Oncol Lett       Date:  2019-11-13       Impact factor: 2.967

5.  Apoptosis-Associated Gene Expression Profiling Is One New Prognosis Risk Predictor of Human Rectal Cancer.

Authors:  Qiansan Zhu; Xian Wu; Lili Ma; Haibo Xue
Journal:  Dis Markers       Date:  2022-04-23       Impact factor: 3.464

6.  Preventive action of benztropine on platinum-induced peripheral neuropathies and tumor growth.

Authors:  Olivier Cerles; Tânia Cristina Gonçalves; Sandrine Chouzenoux; Evelyne Benoit; Alain Schmitt; Nathaniel Edward Bennett Saidu; Niloufar Kavian; Christiane Chéreau; Camille Gobeaux; Bernard Weill; Romain Coriat; Carole Nicco; Frédéric Batteux
Journal:  Acta Neuropathol Commun       Date:  2019-01-18       Impact factor: 7.801

7.  The factors that affect the mortality of emergency operated ASA 3 colon cancer patients.

Authors:  Yeliz Yilmaz; Fevzi Cengiz; Erdinç Kamer; Turan Acar; Emine Özlem Gür; Halis Bag; Yasin Peker; Kemal Atahan
Journal:  Pan Afr Med J       Date:  2020-08-17

8.  Radiological assessment of persistent retroperitoneal and lateral pelvic lymph nodes after neoadjuvant therapy for rectal cancer: An analysis of the United States Rectal Cancer Consortium.

Authors:  Michael K Turgeon; Adriana C Gamboa; Jessica M Keilson; Jeffrey Maniko; Lillias Maguire; Katherine Hrebinko; Jennifer Holder-Murray; Jason T Wiseman; Sherif Abdel-Misih; Saif Hamdan; Alexander T Hawkins; Philip Bauer; Matthew Silviera; Shishir K Maithel; Glen C Balch
Journal:  J Surg Oncol       Date:  2021-07-16       Impact factor: 2.885

9.  Resveratrol Chemosensitizes TNF-β-Induced Survival of 5-FU-Treated Colorectal Cancer Cells.

Authors:  Constanze Buhrmann; Mina Yazdi; Bastian Popper; Parviz Shayan; Ajay Goel; Bharat B Aggarwal; Mehdi Shakibaei
Journal:  Nutrients       Date:  2018-07-12       Impact factor: 5.717

10.  Effect of HtrA1 Polymorphism on Sensitivity to Chemotherapy in Patients with Colon Cancer.

Authors:  Yi Yao; Nan Li
Journal:  Med Sci Monit       Date:  2020-03-27
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.